Olaparib applicable population, restrictions, drug interactions
Olaparib is a PARP inhibitor, which is suitable for the treatment of BRCA mutation related ovarian cancer, breast cancer and other malignant tumors. Attention should be paid to restrictions such as bone marrow suppression and embryotoxicity, and there is a risk of interaction with CYP3A4 inhibitors/inducers and other drugs.
1. Applicable population
(1) Advanced ovarian cancer patients carrying BRCA mutations: used for first-line maintenance therapy or maintenance therapy after platinum sensitive recurrence.
(2) HER2 negative BRCA mutation metastatic breast cancer: used for adult patients who have received chemotherapy.
(3) Other indications: prostate cancer, pancreatic cancer, etc. shall be used individually according to the results of gene testing.
2. Restrictive conditions
(1) Bone marrow suppression: may cause anemia and neutropenia, requiring regular monitoring of blood routine.
(2) Pregnancy risk: It has embryo fetal toxicity. Before taking medication, it is necessary to confirm the pregnancy status and take contraceptive measures.
(3) Liver function damage: Moderate to severe damage should be treated with caution, and it is recommended to adjust the dosage.
(4) Breastfeeding period: Medications may be secreted into breast milk. Breastfeeding is prohibited during the treatment period and within one month after the last administration.
3. Drug interactions
(1) Strong CYP3A4 inhibitors (such as clarithromycin): may increase exposure to olaparib and should be avoided in combination or reduced by 50%.
(2) CYP3A4 inducers (such as rifampicin): may reduce the efficacy of olaparib and alternative drugs need to be considered.
(3) BCRP inhibitors: may increase the blood concentration of olaparib and require monitoring for adverse reactions.
4. Special precautions
(1) Myelodysplastic syndrome/acute leukemia: Hematological toxicity should be monitored during treatment.
(2) Pneumonia: Immediate assessment is necessary when new or worsening respiratory symptoms appear.
(3) Dosage regimen: Capsules and tablets are not interchangeable, and the dosage should be strictly adjusted according to the dosage form.
Disclaimer：《Olaparib applicable population, restrictions, drug interactions》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！